



## **Curriculum Vitae**

Name: Gregory P. Adams

Affiliation: Chief Scientific Officer, Eleven Biotherapeutics

Short Biography (maximum of 400 words):

Dr. Adams is Chief Scientific Officer of Eleven Biotherapeutics, a clinical stage company developing Targeted Protein Therapeutics for the treatment of cancer. In this role he is responsible for guiding the development of the company's pipeline assets. Prior to Eleven's acquisition of Viventia Bio, he was Viventia's Chief Development Officer. Before moving to biotech, Dr. Adams was the Director of Biological Research and Therapeutics and previously co-led the Developmental Therapeutics Program at the Fox Chase Cancer Center, an NCI designated comprehensive cancer center in Philadelphia.

Dr. Adams is an immunologist with over 25 years of experience in developing antibody-based agents for the treatment and detection of cancer. He received a Ph.D. in Immunology from the University of California at Davis in 1991. He joined Fox Chase Cancer Center in Philadelphia where he led a laboratory focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer.

Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAb and Cancer Biotherapy & Radiopharmaceuticals. He has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals, Symphogen, Avipep, Viventia Bio, AvidBiologics, Xerion, Fabrus, Integral Molecular and YM Biosciences.

## **Speech Summary at ATC 2017**

**Speech Title:** Developing Targeted Fusion Proteins for the Treatment of Cancer

**Speech Summary (200-400 words)**

Eleven Biotherapeutics is developing Targeted Protein Therapeutics, or TPTs, which are fusion proteins comprised of antibody fragments genetically fused to protein toxins. Our TPTs directly kill dividing and non-dividing targeted tumor cells, are not sensitive to multidrug resistance mechanisms and have the potential to promote host anti-tumor immune responses in a manner that is complimentary to checkpoint inhibitors and other immune-oncology agents. I will discuss our development and clinical evaluation of our local-regional and systemic agents Vicinium, Proxinium and VB6-845d.